Description
PrymaLab · Research use only
Preloaded Autoinjector | VIP5 (Vasoactive Intestinal Peptide) | 3ml Pen | 5mg/ml
Vasoactive intestinal peptide at 5 mg/mL, 3 mL in a preloaded autoinjector pen
Vasoactive intestinal peptide, listed by PrymaLab as VIP5, is a 28-residue neuropeptide that signals through VPAC1 and VPAC2. This listing is a preloaded autoinjector pen with 3 mL of VIP solution at 5 mg/mL, 15 mg of peptide in all, ready without reconstitution. Published work on VIP covers its receptors, its relationship with PACAP and its effects on immune and nerve cells, mostly in cell and animal models.
Specifications
| Property | Value |
|---|---|
| Compound | Vasoactive intestinal peptide (1-28) amide; aviptadil |
| CAS number | 40077-57-4 |
| Molecular formula | C147H238N44O42S |
| Contents | VIP: 15 mg per 3 mL pen (0.5% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle |
| Storage, sealed | Store at 2–8 °C in the original carton, protected from light |
| Safety data sheet | PL-SDS-185 |
What is in the pen
The pen holds 3 mL of VIP at 5 mg/mL, which is 15 mg of peptide. It is the same vasoactive intestinal peptide sold freeze-dried in the VIP5 10 mg vial and the VIP5 5 mg vial. A safety data sheet for the pen itself has not been published, so this page does not state the solvent, any preservative or the storage temperature for the solution; ask PrymaLab for these before the pen is used.
A pen fixes the concentration at filling, while a freeze-dried vial lets the laboratory choose the volume and keeps the peptide dry until it is needed. The general trade-offs are covered in peptide pen vs vial.
What the research covers
VIP belongs to a superfamily of related peptide hormones that also includes glucagon, the glucagon-like peptides, secretin, GIP, GHRH and PACAP1. Its closest relative is PACAP: the two share 68% of their amino acid sequence and act on the same receptors, VPAC1 and VPAC2, which mainly couple to adenylate cyclase and raise cAMP2. PACAP alone has a third, selective receptor, PAC11. VIP is made by neurons and by immune cells, and immune cells carry VIP receptors, which is why reviews describe it as an immune regulator as well as a neurotransmitter, vasodilator and secretagogue3. The IUPHAR review linked VIP and PACAP signalling in the brain to circadian rhythms, memory and stress responses, and in the periphery to insulin secretion and the control of inflammation1.
Most of the evidence on what VIP does comes from receptor pharmacology, transgenic animals and rodent disease models, summarised in reviews rather than trials2. None of the cited work used VIP held in solution in a pen, and none reports how stable VIP is once dissolved. The VIP peptide research guide has the full literature, including half-life and circadian work, and the VIP5 10 mg vial page has a longer summary of the receptor studies.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the pen, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
How does the pen differ from the VIP5 vials?
The vials contain dry peptide that is stored frozen and dissolved in the lab to whatever concentration a study needs. The pen contains the same peptide already in solution at a fixed 5 mg/mL, 15 mg in 3 mL.
What does the certificate cover for the pen?
The lot of peptide that went into the pen, not the finished solution. Certificates are listed on the testing results page and can be confirmed on the verify page by number and key.
Do the published VIP studies apply to the pen?
Only as background. They describe the peptide, its receptors and its effects in cells and animals. The solution in this pen, its concentration and its shelf life were not part of any of them.
Is there a safety data sheet for the pen?
Not yet. The freeze-dried VIP5 vials have one, but the pen does not, so this page gives no solvent or storage details for the solution. Contact PrymaLab for them before use.
Is the pen for human use?
No. It is supplied for laboratory research only, is not approved for human or veterinary use, and nothing on this page is a guide to using it in people or animals.
References
- Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166(1):4-17. DOI · PubMed
- Dickson L, Finlayson K. VPAC and PAC receptors: From ligands to function. Pharmacol Ther. 2009;121(3):294-316. DOI · PubMed
- Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25-39. DOI · PubMed
Research use only
For laboratory research use only. This product is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of VIP5 (Vasoactive Intestinal Peptide)
VIP5 (Vasoactive Intestinal Peptide) is also stocked as VIP 10mg Nasal Spray. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.